Live Price Coverage: ITI Inc Hit 1 Year Low

Live Price Coverage: ITI Inc Hit 1 Year Low

The stock of ITI Inc (NASDAQ:ITCI) hit a new 52-week low and has $10.22 target or 10.00% below today’s $11.36 share price. The 8 months bearish chart indicates high risk for the $451.16M company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $10.22 price target is reached, the company will be worth $45.12M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 356,874 shares traded hands. ITI Inc (NASDAQ:ITCI) has declined 58.27% since April 1, 2016 and is downtrending. It has underperformed by 59.48% the S&P500.

ITI Inc (NASDAQ:ITCI) Ratings Coverage

Out of 8 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Intra-Cellular Therapies has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of ITI Inc (NASDAQ:ITCI) has “Market Perform” rating given on Thursday, September 29 by JMP Securities. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, November 6 report. The stock has “Neutral” rating given by SunTrust on Thursday, September 29. As per Friday, August 7, the company rating was upgraded by Zacks. The firm has “Overweight” rating given on Thursday, June 2 by Piper Jaffray. The rating was maintained by Guggenheim on Thursday, September 17 with “Buy”. JMP Securities maintained ITI Inc (NASDAQ:ITCI) on Wednesday, March 9 with “Market Outperform” rating.

According to Zacks Investment Research, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.”

Insitutional Activity: The institutional sentiment increased to 1.71 in Q2 2016. Its up 0.25, from 1.46 in 2016Q1. The ratio improved, as 17 funds sold all ITI Inc shares owned while 28 reduced positions. 23 funds bought stakes while 54 increased positions. They now own 30.01 million shares or 2.84% more from 29.18 million shares in 2016Q1.
Great Point Partners Limited Liability, a Connecticut-based fund reported 100,000 shares. Fiera, a Quebec – Canada-based fund reported 18,320 shares. Dubuque Savings Bank Trust has 250 shares for 0% of their US portfolio. Ubs Asset Americas accumulated 0% or 18,100 shares. Pnc Financial Ser Gru accumulated 36,367 shares or 0% of the stock. Frontier Management Ltd Liability Corp accumulated 81,999 shares or 0.03% of the stock. Lord Abbett And Company Ltd last reported 64,816 shares in the company. Gilder Gagnon Howe And Ltd Liability Corp last reported 0.23% of its portfolio in the stock. Us Fincl Bank De has 0% invested in the company for 814 shares. Moreover, Redmile Grp Ltd has 3.6% invested in ITI Inc (NASDAQ:ITCI) for 971,565 shares. Rhumbline Advisers, a Massachusetts-based fund reported 33,281 shares. Gam Hldgs Ag holds 61,400 shares or 0.04% of its portfolio. Swiss Bank & Trust owns 54,700 shares or 0% of their US portfolio. Parametric Associates Limited Com last reported 24,633 shares in the company. Trexquant Investment L P holds 0.04% or 8,581 shares in its portfolio.

Another recent and important ITI Inc (NASDAQ:ITCI) news was published by Businesswire.com which published an article titled: “ITI and FAC Merge to Form KINEXO” on September 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment